# CSPC Ouyi Pharmaceutical Co., Ltd. trials: 30 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with CSPC Ouyi Pharmaceutical Co., Ltd. as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CSPC Ouyi Pharmaceutical Co., Ltd.: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cspc-ouyi-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07881991 | Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Respiratory Syncytial Virus Infections | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881991) |
| September 4, 2026 | NCT07803991 | Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803991) |
| September 1, 2026 | NCT07796477 | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796477) |
| July 30, 2026 | NCT07736404 | A Study of SYH2082 Injection in Healthy Participants | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Overweight or Obesity | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736404) |
| July 30, 2026 | NCT07736391 | A Study of SYH2069 Injection in Healthy Participants | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Overweight or Obesity, Diabetes | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736391) |
| June 3, 2026 | NCT07623915 | A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Primary Hyperlipidemia | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623915) |
| April 9, 2026 | NCT07519109 | Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Postoperative Pain | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519109) |
| November 20, 2025 | NCT07239765 | A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Completed | Invasive Mold Disease | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239765) |
| June 18, 2025 | NCT07026968 | A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Type 2 Diabetes | 815 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026968) |
| May 6, 2025 | NCT06958692 | A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Major Depressive Disorder (MDD) | 388 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06958692) |
| April 25, 2025 | NCT06943950 | A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Moderate to Severe Plaque Psoriasis | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943950) |
| August 26, 2024 | NCT06571461 | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant... | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Pancreatic Cancer | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06571461) |
| August 20, 2024 | NCT06562894 | Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Severe Alopecia Areata | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06562894) |
| July 22, 2024 | NCT06511739 | A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Unknown | Non-segmental Vitiligo | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06511739) |
| June 11, 2024 | NCT06451666 | Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Presbyopia | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06451666) |
| April 25, 2024 | NCT06383702 | A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Painful Diabetic Neuropathy | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383702) |
| April 11, 2024 | NCT06360445 | Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Participants | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06360445) |
| April 9, 2024 | NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Advanced Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06354114) |
| May 15, 2023 | NCT05858047 | An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Completed | Effects, Drug Side | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05858047) |
| March 3, 2023 | NCT05753865 | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for... | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Advanced Breast Cancer | 454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05753865) |
| February 15, 2023 | NCT05728541 | Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Advanced Malignant Tumors | 367 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05728541) |
| February 1, 2023 | NCT05707832 | A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | Completed | Invasive Candidiasis, Invasive Aspergillosis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05707832) |
| November 8, 2022 | NCT05609019 | A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumors | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05609019) |
| March 11, 2022 | NCT05274893 | A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Advanced Breast Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05274893) |
| September 17, 2021 | NCT05047991 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated... | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Unknown | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05047991) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 10 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 10 |
| Not yet recruiting | 8 |
| Completed | 6 |
| Active not recruiting | 3 |
| Recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Overweight | 3 |
| Obesity | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Pain, Postoperative | 1 |
| Pancreatic Neoplasms | 1 |
| Cholangiocarcinoma | 1 |
| Gallbladder Neoplasms | 1 |
| Presbyopia | 1 |
| Respiratory Syncytial Virus Infections | 1 |
| Diabetes Mellitus | 1 |
| Diabetic Neuropathies | 1 |
| Small Cell Lung Carcinoma | 1 |
| Alopecia Areata | 1 |
| Candidiasis, Invasive | 1 |
| Depressive Disorder, Major | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
